Table 1 Baseline characteristics for 6,750 GLP1-RA users and 4,210 patients undergoing BS included in our study population
From: Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery
Study | Ancestry | No. of individuals | Proportion of women (%) | Mean body weight at baseline (s.d.) | Mean age at baseline (s.d.) | T2D prevalence (%) | Most common GLP1-RA type | Proportion of semaglutide (%) |
|---|---|---|---|---|---|---|---|---|
GLP1-RA | ||||||||
HUS | EUR | 255 | 68.00 | 113.70 (22.90) | 53.79 (13.52) | 65.49 | Semaglutide | 60.40 |
ESTBB | EUR | 191 | 62.30 | 109.18 (20.3) | 56.95 (10.96) | 89.01 | Semaglutide | 72.77 |
UKBB | EUR | 614 | 44.30 | 105.00 (19.90) | 60.50 (7.15) | 99.80 | Liraglutide | 0.00 |
AoU | EUR | 117 | 64.96 | 106.66 (24.18) | 57.01 (11.03) | 82.91 | Liraglutide | 11.97 |
AFR | 91 | 83.52 | 104.8 (25.01) | 54.57 (11.93) | 92.31 | Liraglutide | 18.68 | |
MGBB | EUR | 857 | 57.01 | 99.99 (21.48) | 59.88 (12.17) | 56.33 | Semaglutide | 40.72 |
AFR | 156 | 54.32 | 104.65 (23.80) | 54.31 (11.91) | 60.24 | Dulaglutide | 36.14 | |
BioMe | AMR | 614 | 66.45 | 91.19 (22.45) | 59.07 (11.29) | 67.75 | Dulaglutide | 29.32 |
AFR | 728 | 69.78 | 101.49 (25.42) | 57.00 (12.24) | 69.50 | Dulaglutide | 29.12 | |
EUR | 369 | 44.44 | 98.26 (21.93) | 60.32 (11.57) | 47.97 | Semaglutide | 37.13 | |
SAS | 77 | 50.65 | 83.79 (20.10) | 56.48 (12.59) | 70.13 | Semaglutide | 41.56 | |
UCLA-ATLAS | AFR | 133 | 64.00 | 101.6 (23.20) | 61.00 (13.00) | 91.00 | Semaglutide | 57.10 |
AMR | 336 | 66.00 | 94.40 (22.60) | 56.00 (13.00) | 84.00 | Liraglutide | 26.50 | |
EAS | 120 | 47.00 | 81.50 (16.30) | 60.00 (13.00) | 92.00 | Semaglutide | 61.70 | |
EUR | 856 | 53.00 | 101.60 (22.00) | 63.00 (13.00) | 80.00 | Semaglutide | 67.80 | |
QBB | MID | 1,236 | 72.17 | 97.68 (24.54) | 49.52 (10.75) | 75.97 | Liraglutide | 3.64 |
Bariatric surgery | ||||||||
HUS | EUR | 378 | 81.00 | 113.63 (19.5) | 49.90 (9.39) | 37.04 | ||
ESTBB | EUR | 273 | 76.56 | 121.24 (20.57) | 44.72 (10.07) | 28.21 | ||
UKBB | EUR | 196 | 69.40 | 121.00 (29.70) | 55.50 (8.21) | 50.00 | ||
AoU | EUR | 168 | 81.55 | 121.32 (29.88) | 50.74 (12.62) | 18.45 | ||
AFR | 183 | 89.62 | 127.23 (32.55) | 46.09 (11.67) | 48.63 | |||
MGBB | EUR | 978 | 71.06 | 121.21 (26.52) | 49.37 (12.16) | 39.98 | ||
AFR | 150 | 86.67 | 122.89 (23.92) | 43.68 (11.67) | 42.67 | |||
BioMe | AMR | 143 | 79.72 | 112.36 (20.81) | 44.62 (11.48) | 30.07 | ||
AFR | 188 | 82.98 | 124.88 (25.63) | 45.35 (12.16) | 29.26 | |||
EUR | 51 | 70.59 | 120.23 (25.29) | 49.51 (13.34) | 17.65 | |||
QBB | MID | 1,147 | 69.49 | 102.14 (23.18) | 41.66 (10.66) | 40.02 | ||
BBSS | EUR | 355 | 56.06 | 138.48 (27.07) | 47.10 (7.11) | 35.21 | ||
